Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia

Phase 4CompletedNCT00174330

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.330 enrolled

Overview

To evaluate efficacy of the dual therapy of atorvastatin + amlodipine vs. amlodipine alone .

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

330

Conditions

Hypertension Hyperlipidemia

Interventions

atorvastatinDRUG

amlodipineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with a diagnosis of both hyperlipidemia and hypertension. Exclusion Criteria: * Subjects with Type 1 diabetes mellitus or Type 2 diabetes mellitus. * Subjects with other atherosclerotic disease.

Locations (15)

Pfizer Investigational Site

Beijing, Beijing Municipality, China

Pfizer Investigational Site

Guangzhou, Guangdong, China

Pfizer Investigational Site

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

To evaluate efficacy of the dual therapy of atorvastatin 10mg or 20mg + amlodipine 5mg or 10mg vs. amlodipine 5mg or 10mg alone

Secondary Outcomes

To provide comparative evaluation of the safety profile of the dual therapy with atorvastatin + amlodipine versus amlodipine alone.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.